Provided herein are novel sugar derivatives which are intermediates for preparing senolytic agents that selectively kill senescent cells associated with numerous pathologies and diseases, including age-related pathologies and diseases.

Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease.

Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease.

Disclosed are processes for the production of composition comprising one or more fructose amino acids, and related. Such a process may comprise the steps of: (a) providing plant material derived from a botanical source selected from plants of the families Solanaceae, Compositae, Asteraceae, Guttiferae, Umbelliferae, Papaveraceae, Vitidaceae or Acanthaceae; (b) extracting one or more fructose amino acid(s) from said plant material; and optionally, (c) detecting the presence and/or measuring the amount of said fructose amino acid(s) in the extract of step (b).

Disclosed are processes for the production of composition comprising one or more fructose amino acids, and related. Such a process may comprise the steps of: (a) providing plant material derived from a botanical source selected from plants of the families Solanaceae, Compositae, Asteraceae, Guttiferae, Umbelliferae, Papaveraceae, Vitidaceae or Acanthaceae; (b) extracting one or more fructose amino acid(s) from said plant material; and optionally, (c) detecting the presence and/or measuring the amount of said fructose amino acid(s) in the extract of step (b).

The present disclosure relates to 2-alkynylmannose Derivative and Application Thereof. The mannose derivatives, and a pharmaceutically acceptable salt, an isotope, and an isomer thereof have a structure shown as formula I: ##STR00001##
and are used for treating or preventing bacterial infections. The present disclosure also provides pharmaceutically acceptable compositions comprising the above compounds and their use in the treatment or prevention of bacterial infections.

The present invention relates to compounds of the following formula (I): as well as their preparation process; their use in cosmetic or dermatological applications, in particular for the treatment and/or prevention of skin aging, skin protection or skin regeneration; for skin plumping and/or skin volumizing and/or skin densifying, and/or wrinkle filling and/or skin or hair moisturising and/or skin or hair relipiding and/or stimulation of hair growth; for the treatment of dry skin and/or atopic dermatitis and/or eczema and/or psoriasis; for the treatment and/or prevention of a fibrosis disease (e.g. an excessive scar such as a keloid or hypertrophic scar) or for healing; or for the treatment of inflammation (e.g. chronic, low-grade inflammation); and their use as adjuvant for preservation and/or protection and/or regeneration of a biological material or a microorganism.

##STR00001##

The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies.

The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies.

Disclosed are linear discrete PEG constructs, which can be created and produced in a precise and reproducible way. Key to being able to do these things, where x in the discrete PEG.sub.x can vary from about 2 to about 64, is that the processes used to make each linear portion is controlled to give essentially one oligomer/one compound. Having a variable length linear discrete PEG construct that is (a) primarily an linear discrete PEG construct with diagnostic or therapeutic groups attached along a chain of attachment cores, which is attached to a preferential locator; (b) is an m-discrete PEG as the terminal construct on the linear portion, and hidden; (c or linear discrete PEG with a terminus group that can be either negatively or positively charged, or neutral; and any of the discrete PEG portions can be designed to be cleaved after entering the cell.